Ac­cess to methotrex­ate in lim­bo post-Roe — re­port

On the heels of the Supreme Court’s de­ci­sion to over­turn Roe v. Wade, some women have said they’ve had trou­ble ac­cess­ing methotrex­ate — a com­mon drug for au­toim­mune dis­eases and can­cer that’s al­so used off-la­bel to end ec­topic preg­nan­cies.

The Lu­pus Foun­da­tion of Amer­i­ca con­firmed on Mon­day that it’s aware of re­ports that peo­ple have had dif­fi­cul­ty get­ting a hold of methotrex­ate. The drug was de­vel­oped more than sev­en decades ago as a chemother­a­py agent, but is now com­mon­ly used to treat au­toim­mune con­di­tions such as rheuma­toid arthri­tis and lu­pus. Just last week, Hori­zon Ther­a­peu­tics land­ed an ex­pand­ed la­bel for its gout med­i­cine Krys­texxa in com­bi­na­tion with methotrex­ate.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER